Inhibrx Biosciences Files 8-K on Security Holder Vote
Ticker: INBX · Form: 8-K · Filed: May 28, 2025 · CIK: 2007919
| Field | Detail |
|---|---|
| Company | Inhibrx Biosciences, Inc. (INBX) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Inhibrx Biosciences is holding a shareholder vote on May 28, 2025.
AI Summary
On May 28, 2025, Inhibrx Biosciences, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The company, formerly known as Ibex SpinCo, Inc. until January 11, 2024, is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates that Inhibrx Biosciences is seeking approval from its shareholders on certain matters, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine procedural announcement regarding a shareholder vote and does not disclose any new material financial or operational risks.
Key Players & Entities
- Inhibrx Biosciences, Inc. (company) — Registrant
- Ibex SpinCo, Inc. (company) — Former company name
- May 28, 2025 (date) — Date of report and earliest event
- 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037 (location) — Principal Executive Offices
FAQ
What specific matters are being submitted for a vote by Inhibrx Biosciences' security holders?
The filing states that matters are being submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
When was Inhibrx Biosciences, Inc. formerly known as Ibex SpinCo, Inc.?
The company was formerly known as Ibex SpinCo, Inc. until January 11, 2024.
What is the principal executive office address for Inhibrx Biosciences, Inc.?
The principal executive offices are located at 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the fiscal year end for Inhibrx Biosciences, Inc.?
The fiscal year end for Inhibrx Biosciences, Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Inhibrx Biosciences, Inc. (INBX).